|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07F 9/12 | (2006.01) |
| C07F 9/65586 | (2013.01) | ||
| A61K 31/661 | (2006.01) | ||
| C07D 311/30 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07D 311/22 | (2013.01) | ||
| C07D 405/04 | (2013.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 31/38 | (2013.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3527574 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19167051.2 |
| Date of filing the European patent application | 2016-05-18 | |
| (97) | Date of publication of the European application | 2019-08-21 |
| (45) | Date of publication and mention of the grant of the patent | 2022-04-06 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201562163188 P | 2015-05-18 | US |
| (72) |
SIDDIQUI-JAIN, Adam , US
BEARSS, David J. , US
|
| (73) |
Sumitomo Pharma Oncology, Inc. ,
640 Memorial Drive, Cambridge, MA 02139,
US
|
| (54) | ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY |
| ALVOCIDIB PRODRUGS HAVING INCREASED BIOAVAILABILITY |